Clinical observation and literature review of PD-1 antibody in the treatment of 18 patients with advanced tumor

XIA Yong; KOU Xiaoxia; YANG Xijing; ZHOU Fuping; ZHANG Qian; QIAN Qijun

doi:10.3969/j.issn.1006-0111.2017.02.020

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To observe the immune effect of PD-1 (programmed death-1) antibody in the treatment of patients with advanced cancer. Methods From October 2015 to March 2016, 18 patients with advanced tumor were selected to receive the PD-1 antibody treatment in Eastern Hepatobiliary Surgical Hospital. Clinical efficacy, adverse reactions and progression free survival time were monitored. The quality of life were compared before and after the treatment. Results Among 18 cases, PR 5 cases, SD 7 cases and PD 6 cases. The KPS scores for quality of life was significantly increased (P<0.05) after treatment. At the end of follow-up, 5 patients died, 2 patients were lost in follow-up, 11 patients survived. The median progression free survival was 2.6 months (95% CI:1.8-3.3 months). No serious adverse reactions and abnormal laboratory results were reported. Conclusion PD-1 antibody is a safe and effective treatment for advanced tumors. It is well tolerated and has less adverse reactions. The randomized control studies with larger samples are needed to further confirm our conclusions.

Clinical observation and literature review of PD-1 antibody in the treatment of 18 patients with advanced tumor

Department of Bio-therapy, Eastern Hepatobiliary Surgical Hospital Affiliated to Second Military Medical University, Shanghai 201805, China

Received Date: 2016-04-28

Rev Recd Date: 2016-12-07

Key words:

Abstract: Objective To observe the immune effect of PD-1 (programmed death-1) antibody in the treatment of patients with advanced cancer. Methods From October 2015 to March 2016, 18 patients with advanced tumor were selected to receive the PD-1 antibody treatment in Eastern Hepatobiliary Surgical Hospital. Clinical efficacy, adverse reactions and progression free survival time were monitored. The quality of life were compared before and after the treatment. Results Among 18 cases, PR 5 cases, SD 7 cases and PD 6 cases. The KPS scores for quality of life was significantly increased (P<0.05) after treatment. At the end of follow-up, 5 patients died, 2 patients were lost in follow-up, 11 patients survived. The median progression free survival was 2.6 months (95% CI:1.8-3.3 months). No serious adverse reactions and abnormal laboratory results were reported. Conclusion PD-1 antibody is a safe and effective treatment for advanced tumors. It is well tolerated and has less adverse reactions. The randomized control studies with larger samples are needed to further confirm our conclusions.

HTML

Reference (13)

[1]	de Koning HJ, Meza R,Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies:a comparative modeling study for the U.S. Preventive Services Task Force[J]. Ann Intern Med,2014,160(5):311-320.
[2]	Rucci N,Angelucci A.Postate cancer and bone:the elective affinities[J]. Biomed Res Int,2014,2014:167035.
[3]	Zuo TT, Zheng RS, Zhang SW, et al. Incidence and mortality of liver cancer in China in 2011[J]. Chin J Cancer,2015,34(11):508-513.
[4]	Kirkwood JM, Butterfield LH, Tarhini AA,et al. Immunotherapy of cancer in 2012[J]. CA Cancer J Clin,2012,62(5):309-335.
[5]	Zak KM, Grudnik P, Guzik K, et al. Structural basis for small molecule targeting of the programmed death ligand 1(PD-L1)[J]. Oncotarget,2016,7(21):30323- 30335.
[6]	Muenst S, Läubli H, Soysal SD,et al.The immune system and cancer evasion strategies:therapeutic concepts[J]. J Intern Med,2016,279(6):541-562.
[7]	Trivedi MS, Hoffner B, Winkelmann JL,et al.Programmed death 1 immune checkpoint inhibitors[J]. Clin Adv Hematol Oncol,2015,13(12):858-868.
[8]	Chakravarti N, Prieto VG. Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs:immunohisto chemistry analysis[J]. Transl Lung Cancer Res,2015,4(6):743-751.
[9]	Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab[J]. J Clin Oncol,2014,32(10):1020-1030.
[10]	Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma[J]. N Engl J Med,2015,373(1):23-34.
[11]	Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med,2015,373(17):1627-1639.
[12]	Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma[J]. N Engl J Med, 2015,373(19):1803-1813.
[13]	Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med,2012,366(26):2455-2465.

Message Board

Clinical observation and literature review of PD-1 antibody in the treatment of 18 patients with advanced tumor

doi: 10.3969/j.issn.1006-0111.2017.02.020

Abstract

References

Proportional views

通讯作者: 陈斌, [email protected]

Article Metrics

Related

Proportional views